Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pacira Pharm Inc
(NQ:
PCRX
)
17.55
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pacira Pharm Inc
< Previous
1
2
3
Next >
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
November 14, 2024
-- Poster to be presented at ACR Convergence annual meeting --
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
November 12, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
November 04, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
October 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
October 21, 2024
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
October 03, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
September 26, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 09, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
August 09, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Second Quarter 2024 Financial Results
July 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
July 23, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
July 10, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
May 10, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
May 08, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
May 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
April 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
March 20, 2024
Via
AB Newswire
Topics
Death
Exposures
Death
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
March 13, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
March 06, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
February 22, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
February 15, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
February 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
January 04, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Pacira BioSciences
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.